ENBREL Dosing for Moderate to Severe Rheumatoid Arthritis (RA)

ENBREL is an injection that might fit easily into your schedule. Your doctor will tell you how often you should use ENBREL. Do NOT use ENBREL more often than prescribed.

Rheumatoid arthritis dosing

The recommended dose of ENBREL for adult patients with moderately to severely active rheumatoid arthritis (RA) is50 mg per week. A 50 mg dose can be given as one subcutaneous injection (an injection beneath the skin) using either a 50 mg/mL Enbrel® SureClick® autoinjector or a 50 mg/mL single-use prefilled syringe. A 50 mg dose can also be given as two 25 mg subcutaneous injections using 25 mg/0.5 mL single-use prefilled syringes or 25 mg vials.

Do NOT miss any doses of ENBREL. Call your doctor if you miss a dose of ENBREL. Your doctor will tell you if and when you should take your missed dose.

Injection site reactions such as redness, rash, swelling, itching, or bruising
may occur. These symptoms usually go away within 3 to 5 days. If you experience
these reactions and they get worse or don't go away, call your doctor.
Please see Prescribing Information, Important Safety Information, and Medication Guide for complete details about ENBREL.

Tip: Set aside a specific time every week to prepare and take your injection of ENBREL.

Need injection help?

Watch easy-to-follow videos and see how others self-inject ENBREL after receiving instructions from their healthcare provider.

ENBREL is indicated for reducing signs and symptoms, keeping joint damage from getting worse, and improving physical function in patients with moderate to severe rheumatoid arthritis. ENBREL can be taken with methotrexate or used alone.

Supportive data

Moderate to Severe Rheumatoid Arthritis (RA)

In medical studies, ENBREL was shown to be clinically effective in about 2 out of 3 adults with moderate to severe RA at 3 months. ENBREL has been shown to begin working in as few as 2 weeks, and most patients who benefit will do so within 3 months. In another medical study, 55% of patients who were evaluated 5 years after beginning ENBREL therapy had no further progression of joint damage.